<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="365">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05156398</url>
  </required_header>
  <id_info>
    <org_study_id>BHV3000-315</org_study_id>
    <nct_id>NCT05156398</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety Study of Rimegepant for the Preventative Treatment of Migraine in Pediatric Subjects</brief_title>
  <official_title>A Phase 3, Randomized, Doubleblind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Rimegepant in Migraine Prevention in Children and Adolescents ≥ 6 to &lt;18 Years of Age</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Biohaven Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Biohaven Pharmaceutical Holding Company Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Biohaven Pharmaceuticals, Inc.</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the efficacy and safety of rimegepant to placebo as a&#xD;
      preventative treatment for migraine in children and adolescents ≥ 6 to &lt;18 years with&#xD;
      episodic migraine.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 15, 2021</start_date>
  <completion_date type="Anticipated">September 2, 2026</completion_date>
  <primary_completion_date type="Anticipated">September 2, 2026</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in the mean number of migraine days per month as measured over the 12-week double-blind phase of the study in adolescents with episodic migraine</measure>
    <time_frame>3 months (12 weeks)</time_frame>
    <description>Reduction from baseline in mean number of migraine days per month</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Achievement of at least a 50% reduction from baseline in mean monthly migraine days over the course of the double-blind phase in adolescents with episodic migraine</measure>
    <time_frame>3 months (12 weeks)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in the mean number of migraine days per month in the first 4 weeks (Weeks 1 through 4) of the double-blind treatment phase in adolescents with episodic migraine.</measure>
    <time_frame>Weeks 1 through 4 of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The mean change from baseline in the Pediatric Quality of Life (PedsQLTM) total score at Week 12 of the double-blind treatment phase in adolescents with episodic migraine.</measure>
    <time_frame>Total score at week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in the mean number of migraine days per month over the entire course of the double-blind treatment phase in children and children and adolescents combined with episodic migraine.</measure>
    <time_frame>3 months (12 weeks)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline on the proportion of subjects that have at least a 50% reduction in the mean number of moderate to severe migraine days per month.</measure>
    <time_frame>3 months (12 weeks)</time_frame>
    <description>Measured over the entire course of the double-blind treatment phase in children and children and adolescents combined with episodic migraine.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compare the use of acute migraine-specific medications (triptans) based on the change from baseline in monthly acute migraine specific medication days.</measure>
    <time_frame>3 months (12 weeks)</time_frame>
    <description>Measured in each month and over the course of the entire double-blind treatment phase in adolescents, children and adolescents and children combined.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the safety and tolerability of rimegepant as a preventative treatment for migraine in children and adolescents.</measure>
    <time_frame>72 Weeks</time_frame>
    <description>This will be evaluated by the number of subjects with treatment related adverse events by severity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the frequency of hepatic-related adverse events in subjects treated with rimegepant.</measure>
    <time_frame>72 Weeks</time_frame>
    <description>Measured by discontinuations in treated subjects due to elevated liver function tests.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">1100</enrollment>
  <condition>Migraine</condition>
  <arm_group>
    <arm_group_label>Rimegepant / BHV3000</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Rimegepant 75mg or 50mg (2 X 25mg) ODT</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Matching Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matching placebo 75mg or 50mg (2 X 25mg) ODT</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rimegepant</intervention_name>
    <description>Rimegepant 75mg or 50mg (2 X 25mg) ODT</description>
    <arm_group_label>Rimegepant / BHV3000</arm_group_label>
    <other_name>BHV3000</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Matching placebo 75mg or 50mg (2 X 25mg) ODT</description>
    <arm_group_label>Matching Placebo</arm_group_label>
    <other_name>Matching Placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Subject has at least a 6 month history of migraine (with or without aura) and&#xD;
             including the following:&#xD;
&#xD;
               1. 14 or less headache days per month during the 3 month period prior to the&#xD;
                  Screening Visit&#xD;
&#xD;
               2. 6 or more migraine days during the Observation Period&#xD;
&#xD;
               3. 14 or less headache days during the Observation Period&#xD;
&#xD;
               4. Pediatric Migraine Disability Assessment Scale (PedMIDAS) Disability Score of &gt;10&#xD;
                  to ≤50, indicating mild (score of 11 to 30) or moderate (score of 31 to 50)&#xD;
                  disruption in daily activities, as assessed at the Baseline (Randomization) Visit&#xD;
&#xD;
               5. Ability to verbally distinguish migraine attacks from tension/cluster or other&#xD;
                  types of headaches&#xD;
&#xD;
               6. Migraine attacks, on average, lasting 4 - 72 hours if untreated&#xD;
&#xD;
               7. Subjects on prophylactic migraine medication are permitted to remain on therapy&#xD;
                  if the dose has been stable for at least 3 months (12 weeks) prior to the&#xD;
                  Screening Phase, and the dose is not expected to change during the course of the&#xD;
                  study. 2) Male and female subjects ≥ 6 to &lt;18 years; subjects must be less than&#xD;
                  18 at the time of signing assent / consent.&#xD;
&#xD;
                  3)Subjects must have a weight of ≥40 kg (child cohort requirement ≥15 kg) at the&#xD;
                  Screening Visit.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Subjects with a history of basilar migraine, cluster headaches, or hemiplegic migraine&#xD;
&#xD;
          2. The subject has a continuous migraine (defined as an unrelenting headache) within 1&#xD;
             month prior to Screening Visit.&#xD;
&#xD;
          3. The subject has a history or diagnosis of complications of migraine&#xD;
&#xD;
          4. The subject has a confounding and clinically significant pain syndrome that may&#xD;
             interfere with the subject's ability to participate in this study.&#xD;
&#xD;
          5. The subject has any current psychiatric condition that is uncontrolled and/or&#xD;
             untreated for a minimum of 6 months prior to the Screening Visit. Subjects with a&#xD;
             lifetime history of psychosis and/or mania are excluded.&#xD;
&#xD;
          6. History of suicidal behavior or the subject is at risk of self-harm or harm to others.&#xD;
&#xD;
          7. History of major psychiatric disorder.&#xD;
&#xD;
          8. The subject has a current diagnosis or history of substance abuse&#xD;
&#xD;
          9. The subject has a history of moderate or severe head trauma or other neurological&#xD;
             disorder (including seizure disorder) or systemic medical disease that is, in the&#xD;
             investigator's opinion, likely to affect central nervous system functioning.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Elyse Stock, MD</last_name>
    <phone>203-404-0410</phone>
    <email>clinicaltrials@biohavenpharma.com</email>
  </overall_contact>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 19, 2021</study_first_submitted>
  <study_first_submitted_qc>November 30, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">December 14, 2021</study_first_posted>
  <last_update_submitted>November 30, 2021</last_update_submitted>
  <last_update_submitted_qc>November 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">December 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Migraine, migraine prevention, phonophobia, photophobia, nausea, pediatric migraine, adolescent migraine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Migraine Disorders</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

